OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Final Protocol-Prespecified Analysis of the Phase 3 KEYNOTE-564 Trial of Adjuvant Pembrolizumab Versus Placebo in Clear Cell Renal Cell Carcinoma (ccRCC) @DrChoueiri @tompowles1 @HowardGurney 🔬 Phase 3 (n=994): adjuvant pembrolizumab vs placebo after nephrectomy in ccRCC at high risk of recurrence. Final prespecified analysis; median follow-up 85.9 mo. ➡️ DFS HR 0.68 (0.56–0.82); 7-yr DFS 57.2% vs 44.6% ➡️ OS HR 0.70 (0.53–0.92); 7-yr OS 82.3% vs 76.6% ➡️ No new serious treatment-related AEs ✅ DFS and OS benefits remained consistent with earlier reports, supporting adjuvant pembrolizumab as standard treatment for ccRCC at increased risk of recurrence. #KidneyCancer 🎙️ Toni Choueiri 👥 Naomi Haas · Thomas Powles · Piotr Tomczak · Se Hoon Park · Balaji Venugopal · Stefan Symeonides · Thomas Ferguson · Yen-Hwa Chang · Jae-Lyun Lee · Piotr Sawrycki · Naveed Sarwar · Howard Gurney · Marine Gross-Goupil · John Burke · Gurjyot Doshi · Jerry Cornell · Joseph Burgents · Rodolfo Perini (4Sight Made from Abstracts publicly available at the ESMO website) Pinging Our Faculty @DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper